Literature DB >> 27788463

Peripheral adenosine levels in euthymic patients with bipolar disorder.

Carolina Gubert1, Cesar Eduardo Jacintho Moritz2, Mirela Paiva Vasconcelos-Moreno3, Bárbara Tietböhl Martins Quadros Dos Santos3, Juliana Sartori3, Adam Fijtman3, Márcia Kauer-Sant'Anna4, Flávio Kapczinski5, Ana Maria Oliveira Battastini6, Pedro Vieira da Silva Magalhães7.   

Abstract

Recent evidence points to the involvement of the purinergic signaling in the pathophysiology of bipolar disorder. The aim of this study was to assess the serum levels of adenosine and to evaluate its relation to functioning in 24 euthymic patients with bipolar disorder type I and in 25 matched healthy controls. Subjects were evaluated using the functioning assessment short test. Serum purine levels were measured by high pressure liquid chromatography. Our results show a decrease in serum adenosine levels in bipolar disorder patients compared with controls (t= -4.8, df= 43.96, p<0.001). Moreover, a significant negative correlation was found between patient adenosine levels and depression scale scores (r= -0.642, p= 0.001). Higher functional impairment was linked to lower levels of adenosine in patients (rho= -0.551, p= 0.008). Taken together, our results provide evidence for a purinergic imbalance in bipolar disorder, specifically an adenosinergic dysfunction. Our results also indicate a relation between adenosine levels and the functional impairment caused by the disorder, which could demonstrate a potential relation of adenosine levels in worsening of symptoms.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adenosine; Bipolar disorder; Psychosocial functioning; Purinergic signaling; Uric acid

Mesh:

Substances:

Year:  2016        PMID: 27788463     DOI: 10.1016/j.psychres.2016.10.007

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

Review 3.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Does Blood Flow Change according to Mood? Blood Rheology in Bipolar Disorder.

Authors:  Tevfik Kalelioglu; Murat Kocabiyik; Burcu Kok; Pelin Unalan; Sule Sozen; Ozge Yuksel; Nesrin Karamustafalioglu
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

Review 5.  Research progress on adenosine in central nervous system diseases.

Authors:  Ying-Jiao Liu; Jiao Chen; Xun Li; Xin Zhou; Yao-Mei Hu; Shi-Feng Chu; Ye Peng; Nai-Hong Chen
Journal:  CNS Neurosci Ther       Date:  2019-07-23       Impact factor: 5.243

6.  Patients With Drug-Naive Bipolar Disorder in Remission After 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations.

Authors:  Jing-Xu Chen; Li-Gang Zhang; Ke-Zhi Liu; Hong-Mei Chen; Shuang-Jiang Zhou; Ning Wang; Yun-Long Tan; Shao-Li Wang; Alison Jones; Fu-De Yang; Xu-Feng Huang
Journal:  Front Psychiatry       Date:  2019-10-31       Impact factor: 4.157

Review 7.  Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.

Authors:  Silvia Pasquini; Chiara Contri; Stefania Merighi; Stefania Gessi; Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 8.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

9.  Adenosine A2A Receptor Blockade Ameliorates Mania Like Symptoms in Rats: Signaling to PKC-α and Akt/GSK-3β/β-Catenin.

Authors:  Heba Nasr Shalaby; Hala Fahmy Zaki; Afaf Abd Almonim Ain-Shoka; Reham Atef Mohammed
Journal:  Mol Neurobiol       Date:  2022-08-09       Impact factor: 5.682

Review 10.  A Pattern to Link Adenosine Signaling, Circadian System, and Potential Final Common Pathway in the Pathogenesis of Major Depressive Disorder.

Authors:  Xin-Ling Wang; Wilf Gardner; Shu-Yan Yu; Tsvetan Serchov
Journal:  Mol Neurobiol       Date:  2022-08-23       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.